The results of the SPRINT trial included 9361 hypertensive patients 50 years of age or older randomized to either a standard systolic blood pressure target of 140 mm Hg or an intensive treatment target of 120 mm Hg. The primary (composite) outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure or death from cardiovascular causes. The trial was stopped early by NIH due to a substantial benefit demonstrated in the intensive treatment group.
As compared to patients in the standard treatment group, trial participants in the intensive group had a:
* 25% lower relative risk of the primary outcome
* Lower rate of heart failure (38% relative risk reduction)
* Lower rate of cardiovascular death (43% relative risk reduction)
* Lower rate of death from any cause (27% relative risk reduction)
According to the authors of the study, “The results add substantially to the evidence of benefits of lowering systolic blood pressure, especially in older patients with hypertension. Targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, in patients at high risk for cardiovascular events but without diabetes resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause.”
One of the regimens included the use of the ARB, azilsartin medoxomil and the diuretic, chlorthalidone, an older and less known diuretic. If you want to know why chlorthalidone is such a good choice and why it was the cornerstone diuretic in the landmark SHEP and ALLHAT studies, you will definitely want to check our Item 3. If you want to learn more about the results of the SPRINT study, then click here.
Diabetes Summit 2016
DIC Publisher Steve Freed will be attending the GTCbio 2016 Diabetes Summit, to be held April 25-27, 2016 in Boston, MA. This unique event encompasses the drug discovery and partnering aspects of diabetes in two individual conferences that take place concurrently. Click here for more information.
Free CME Courses
Our web site CME resource is back online! Be sure to check out the new CME courses posted there. Courses are currently available on topics including: Advances in the Medical & Surgical Management of Obesity; Diabetic Retinopathy; Strategies to Improve Prevention and Treatment of Diabetes; and more!
From dLife.com: “dLife brings you the harrowing story of Ernest Sterzer, a type 1 teenage who survived the unthinkable in Nazi Germany. Also, a special tribute to the late, great sports legend, Ron Santo.” Sundays live online at dLifeTV.com at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at dLifeTV.com.
We can make a difference!
Dave Joffe, Editor-in-chief